USANA Health Sciences, Inc.: stock overview

USNANYSEBasic materials · Medicinal Chemicals & Botanical Products

Price

$13.24

November 13, 2026Market cap $244M

DCF calculator

What Ploutos Investor adds for USANA Health Sciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

USANA Health Sciences had revenue of $906M over the last 12 months and a net loss of $21M. Revenue fell by 4.0% a year on average over the last 5 years. It holds more cash than debt, by $179M. It pays no dividend.

From its SEC filings (latest fiscal year to January 3, 2026) and the price of November 13, 2026.

Its SEC filings
Market cap
$244M
18.46M shares
P/E
–
median of 5 years: 16.3
Revenue, 12 months
$906M
-4.0% a year over 5 years
Net margin
-2.3%
FY2025: 1.2%, above 59% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2023–FY2025 fiscal years

+0.2% a year over 2 years

  • FY2025Jan 3, 202610-K
    Revenue$925M
  • FY2024Dec 28, 202410-K
    Revenue$855M
  • FY2023Dec 30, 202310-K
    Revenue$921M

Fiscal years in figures

USNA's revenue, profit, cash flow and dividend with each year-end price, from FY2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $675M
$244M
Enterprise value 
$65M
P/E 3-year median: 16.3
–
EV / EBIT 
–
EV / Revenue 
0.1
P/B 3-year median: 1.3
0.5
FCF yield 3-year median: 5.4%
12.1%
Earnings yield 3-year median: 6.1%
–

Profitability

Gross margin 
77.3%
Operating margin 
-0.4%
Net margin 3-year median: 4.9%
-2.3%
ROIC 
-0.6%
ROIC, 5-year average 
16.8%
ROE 
-4.0%

Growth

Revenue, yearly change 
+8.3%
EPS, yearly change 
-73.5%
FCF, yearly change 
-83.3%
Revenue, average a year 
-4.0%
EPS, average a year 
-37.0%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$179M
Total debt 
$18M
Of which operating leases 
$18M
Net cash 
$179M
Net debt / EBITDA 
-6.2x
Interest cover 
-9.4x
Current ratio 
2.59

Balance sheet of October 3, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
11.26%
Total returned 
11.26%
Shares, yearly change 
-2.4%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

78.3%

Above 93% of the 141 companies in its industry, and 94% of all.

Operating margin

4.1%

Above 60% of the 285 companies in its industry, and 47% of all.

Net margin

1.2%

Above 59% of the 302 companies in its industry, and 39% of all.

ROE

2.0%

Above 58% of the 267 companies in its industry, and 36% of all.

ROA

1.5%

Above 61% of the 313 companies in its industry, and 50% of all.

Revenue growth

8.3%

Above 55% of the 292 companies in its industry, and 57% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
USANA HEALTH SCIENCES INC
CIK
896264
Exchange
NYSE
Industry (SIC)
2833 · Medicinal Chemicals & Botanical Products
Fiscal year ends
January 3
Latest annual report
January 3, 2026
Reporting currency
USD
Shares
18.46M

Other companies: Basic materials

The largest companies of the same sector, each with its own page.

The Basic materials sectorAll companies

The full analysis

What do USANA Health Sciences's filings show?

These are USANA Health Sciences's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about USNA

Didn't find what you were looking for?

Ask us
What is USNA's market cap?

USANA Health Sciences, Inc.'s market cap is $244M, at a price of $13.24 on November 13, 2026 and 18.46M shares.

How much revenue does USNA have?

USANA Health Sciences had revenue of $906M over the last 12 months. Over the last 5 years it changed by -4.0% a year on average.

Does USNA pay a dividend?

No. USANA Health Sciences paid no regular dividend over the last 12 months.

Where do the figures come from?

From USANA Health Sciences, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.